1006 results about "Biosynthetic product" patented technology

Thiazolo-, oxazolo- and selenazolo[4,5-c]quinolin-4-amines and analogs thereof are described including methods of manufacture and the use of novel intermediates. The compounds are immunomodulators and induce cytokine biosynthesis, including interferon and / or tumor biosynthesis, necrosis factor, and inhibit the T-helper-type 2 immune response. The compounds are further useful in the treatment of viral and neoplastic diseases.

Disclosed are improvements in human nutrition involving a unique combination of natural products constituting anti-inflammatory compositions which can reduce cardiovascular disease risks as well as play a positive role in other conditions and diseases for which key indicators, especially selected from the group consisting of C-reactive protein (CRP) levels, cyclooxygenase-2 (COX-2), 5-lypoxygenase (5-LOX) expression and prostaglandin E2 (PGE-2) biosynthesis or any combination of these, are indicators. Therapeutic compositions preferably comprise curcumin, bilberry extract, grape seed extract, green tea extract and apple extract, in effective amounts individually and combined to provide a therapeutically significant reduction in one or more key indicators. Another exemplified therapeutic composition comprises: omega-3 rich refined fish oil, resveratrol, blueberry extract, grape seed extract, green tea extract and gamma and / or delta tocopherol, in effective amounts individually for the above benefits.

Disclosed are mixtures and compositions for controlling invertebrate pests relating to combinations comprising (a) 3-bromo-N-[4-chloro-2-methyl-6-[(methylamino)carbonyl]phenyl]-1-(3-chloro-2-pyridinyl)-1H-pyrazole-5-carboxamide, and its N-oxides, and suitable salts thereof and a component (b) wherein the component (b) is at least one compound or agent selected from neonicotinoids, cholinesterase inhibitors, sodium channel modulators, chitin synthesis inhibitors, ecdysone agonists, lipid biosynthesis inhibitors, macrocyclic lactones, GABA-regulated chloride channel blockers, juvenile hormone mimics, ryanodine receptor ligands, octopamine receptor ligands, mitochondrial electron transport inhibitors, nereistoxin analogs, pyridalyl, flonicamid, pymetrozine, dieldrin, metaflumizone, biological agents, and suitable salts of the foregoing. Also disclosed are methods for controlling an invertebrate pest comprising contacting the invertebrate pest or its environment with a biologically effective amount of a mixture or composition of the invention.

The present invention relates to methods, systems and compositions, including genetically modified microorganisms, adapted to exhibit increased tolerance to 3-hydroxypropionic acid (3-HP), particularly through alterations to interrelated metabolic pathways identified herein as the 3-HP toleragenic pathway complex (“3HPTGC”). In various embodiments these organisms are genetically modified so that an increased 3-HP tolerance is achieved. Also, genetic modifications may be made to provide at least one genetic modification to any of one or more 3-HP biosynthesis pathways in microorganisms comprising one or more genetic modifications of the 3HPTGC.

The present invention is generally directed to diester-based lubricant compositions comprising one or more isomeric mixtures of diester species. The present invention is also directed to methods of making these and other similar lubricant compositions. In some embodiments, the methods for making such diester-based lubricants utilize a biomass precursor material from which mono-unsaturated free lipid species can be provided or otherwise generated, wherein such mono-unsaturated free lipid species arc converted to isomeric diol species en route to the synthesis of diester species for use as / in the diester-based lubricant compositions.

The present invention provides for a method of producing one or more fatty acid derived dicarboxylic acids in a genetically modified host cell which does not naturally produce the one or more derived fatty acid derived dicarboxylic acids. The invention provides for the biosynthesis of dicarboxylic acid ranging in length from C3 to C26. The host cell can be further modified to increase fatty acid production or export of the desired fatty acid derived compound, and / or decrease fatty acid storage or metabolism.

The invention concerns a method and a plant for producing hydrocarbon based fuels from waste and biomass including wood and / or other cellulose containing biomass, where biomass and / or waste is gasified in anaerobic conditions, heating the formed syngas in for decomposition and subsequent condensation in anaerobic conditions, subjecting the heat treated biosyngas to cleaning measures for removing elements / compounds which are poisonous towards the catalysts of the Fischer-Tropsch synthesis, and passing the cleaned heat treated biosyngas through a Fischer-Tropsch synthesis for production of biofuels.

The present invention relates to a process for producing polyunsaturated fatty acids in an organism by introducing nucleic acids into the organism which code for polypeptides having acyl-CoA:lysophospholipid a cyltransferase activity. Advantageously, these nucleic acid sequences may, if appropriate together with further nucleic acid sequences coding for biosynthesis polypeptides of the fatty acid or lipid metabolism, be expressed in the transgenic organism. The invention furthermore relates to the nucleic acid sequences, to nucleic acid constructs comprising the nucleic acid sequences of the invention, to vectors comprising the nucleic acid sequences and / or the nucleic acid constructs and to transgenic organisms comprising the abovementioned nucleic acid sequences, nucleic acid constructs and / or vectors. A further part of the invention relates to oils, lipids and / or fatty acids produced by the process of the invention and to their use.

The intervertebral disc is avascular. With aging, endplates become occluded by calcified layers, and diffusion of nutrients and oxygen into the disc diminishes. The disc degenerates, and pain ensues. Conduits are delivered and deployed into the intervertebral disc to reestablish the exchange of nutrients and waste between the disc and bodily circulation to stop or reverse disc degeneration and relieve pain. The intervertebral disc installed with semi-permeable conduits may be used as an immuno-isolated capsule to encapsulate donor cells capable of biosynthesizing therapeutic molecules. The semi-permeable conduits establish the exchange of nutrients and therapeutic molecules between disc and bodily circulation to treat a disease without using immunosuppressive drugs.

Provided are novel methods for making cellulose nanocomposites, comprising biosynthesis of cellulose fibrils in situ using a growth medium comprising a polymer matrix material, under conditions suitable to provide for dispersion of the fibril throughout the growth medium as the fibrils are being formed to provide a cellulose nanocomposite material or film wherein the cellulose fibrils are highly or uniformly dispersed in the cellulose nanocomposite material, and wherein fibril structure and / or nanocomposite composition is customizable. Certain method aspects further comprise removing or separating the cellulose nanocomposite material or film from the medium, and may further comprise washing the cellulose nanocomposite material or film to remove residual medium. Particular aspects further comprise freeze-drying the cellulose nanocomposite material or film, and / or further comprise forming a molded product using the cellulose nanocomposite material or film. Compositions made by the methods are provided.

Sterile nanoemulsions are prepared containing oily droplets of a diameter of less than 100 nm in an aqueous phase. The oily droplets contain a lipophilic substance, and have on their surface an amphoteric emulsifier in an amount of preferably 0.65 to 0.75 parts by weight amphoteric emulsifier for one part by weight of oily component forming the droplets. The oily component of the droplets is preferably a triglyceride containing oleic acid and / or linoleic acid. The nanoemulsions are used for delivering into cells the lipophilic substance contained by the oily droplets. This delivery can be used to biotransform the lipophilic substance, promote cell differentiation, growth or biosynthesis of a desired substance, or to test for toxicity of the lipophilic substance.

A composite for osteochondral defect repair includes a porous scaffold and a periosteal graft secured to a surface of the scaffold. The composite provides cartilage growth from autologous periosteum chondrogenesis. Biological resurfacing of large osteochondral defects, or a complete joint is feasible using the porous scaffold / autologous periosteal composite. The use of this composite eliminates the necessity of using normal cartilage surface as a donor site and its respective associated morbidity. In one form, the strong bone integration capacity of a porous metal (e.g., tantalum) scaffold and the high grade of integration observed from periosteal chondrogenesis into the normal cartilage eliminates the lack of chondral-chondral integration observed in the autologous osteochondral graft technique.

The intervertebral disc contains no blood vessels. Nutrients and waste are diffused mainly through adjacent vertebral bodies. As we age, calcified layers form between the disc and vertebral bodies, blocking diffusion. The disc begins to starve and flatten. The weight shifts abnormally from disc to the facet joints causing strain and back pain. Under anaerobic conditions, lactic acid is produced causing acidic irritation and unspecific pain. A U-shaped disc shunt is delivered into and sealed within the degenerated disc simply by needle puncturing and withdrawal, to draw nutrients from bodily circulation into the avascular disc. A continual supply of nutrients increases biosynthesis of the water-retaining sulfated glycosaminoglycans, hence swelling pressure within the disc. The weight is re-shifted from the facet joints to the regenerated disc, alleviating back pain. With oxygen transported through the shunt, anaerobic production of lactic acid is minimized. In addition, the residual lactic acid is expelled through the U-shaped shunt during disc compression into bodily circulation to alleviate unspecific pain.

Provided are previously uncharacterised markers of cancers, for example colorectal cancers, and uses of these as diagnostic and prognostic markers of cancers, and in particular colorectal cancers. The markers are SEQ ID NO: 1—hnRNP-K; SEQ ID NO:2—HMG-1; SEQ ID NO:3—proteasome subunit alpha type 1; SEQ ID NO:4—bifunctional purine biosynthesis protein; SEQ ID NO:5—ST11; SEQ ID NO:6—annex in IV; SEQ ID NO:7—60 kDa heat shock protein; SEQ ID NO:8—T complex protein 1 beta subunit; SEQ ID NO:9—T complex protein 1 epsilon subunit; SEQ ID NO: 10—mortalin; and SEQ ID NO: 11—TER-ATPase. The invention further provides related methods and materials for the use of the markers in therapeutic intervention in colorectal and other cancers e.g. to specifically target neoplastic cells without causing significant toxicity in healthy tissues, and to provide methods for the evaluation of the ability of candidate therapeutic compounds to modulate the biological activity of cancerous cells from the colon, rectum and other tissues.

The invention relates to a method for biosynthesis of tyrosol in Escherichia coli and application of tyrosol, which belongs to the field of bioengineering technology. According to the method for biosynthesis of tyrosol in Escherichia coli, tyrosine or glucose is used as a substrate, (4-hydroxyphenyl)pyruvic acid is produced under the catalysis of ammonialyase coded by Escherichia coli; (4-hydroxyphenyl)acetaldehyde is produced under the action of the microzyme 4-hydroxyphenylpyruvate decarboxylase; (4-hydroxyphenyl)acetaldehyde is catalyzed by alcohol dehydrogenase so as to produce tyrosol; and a phenylacetaldehyde dehydrogenase gene of Escherichia coli is knocked out at the same time so as to block the transformation channel for (4-hydroxyphenyl)acetaldehyde into (4-hydroxyphenyl)acetic acid and promote accumulation of (4-hydroxyphenyl)acetaldehyde and transformation of (4-hydroxyphenyl)acetaldehyde into tyrosol. The invention provides a novel production approach for tyrosol; and the method lays a foundation for large-scale industrial production of tyrosol and has important economic values and social benefits.

The present disclosure identifies methods and compositions for modifying photoautotrophic organisms, such that the organisms efficiently convert carbon dioxide and light into compounds such as esters and fatty acids. In certain embodiments, the compounds produced are secreted into the medium used to culture the organisms.

Two acyltransferases are provided, suitable for use in the manufacture of microbial oils enriched in omega fatty acids in oleaginous yeast (e.g., Yarrowia lipolytica). Specifically, the genes encoding phophatidylcholine-diacylglycerol acyltransferase (PDAT) and diacylglycerol acyltransferase (DGAT2) have been isolated from Y. lipolytica. These genes encode enzymes that participate in the terminal step in oil biosynthesis in yeast. Each is expected to play a key role in altering the quantity of polyunsaturated fatty acids produced in oils of oleaginous yeasts.

The invention provides competitive immunoassay techniques for high sensitivity detection of delta-9-tetrahydro-cannabinol (cannabis; THC) employing a carrier conjugate of an intermediate in the biosynthesis of cannabis, more particularly 5-pentylresorcinol conjugated to a macromolecular carrier via its hydroxyl groups. By employing such a conjugate with anti-THC antibody in a lateral flow immunochromatography test device convenient on-site testing for low levels of cannabis in liquid samples may be achieved. Such testing is particularly favoured for roadside testing for cannabis in oral fluid samples.

A medical device (10) for insertion into a bodily vessel (6) to treat an aneurysm (5) having an aneurysm neck, the device (10) comprising: a mechanically expandable device (20) expandable from a first position to a second position, said mechanically expandable device (20) is expanded radially outwardly to the second position such that the exterior surface of said mechanically expandable device (20) engages with the inner surface of the vessel (6) so as to maintain a fluid pathway through said vessel (6); a therapeutically effective amount of a chemical compound comprising a biosynthesis accelerator to stimulate cell growth; and a polymer (30, 41, 42) mixed with the chemical compound to manage the release rate of the chemical compound; wherein the mechanically expandable device (20) provides a support for the release of the chemical compound within the aneurysm (5) to stimulate cell growth within the aneurysm (5) and close the aneurysm neck.

The present invention relates to recombinant microorganisms comprising biosynthetic pathways and methods of using said recombinant microorganisms to produce various beneficial metabolites. In various aspects of the invention, the recombinant microorganisms may further comprise one or more modifications resulting in the reduction or elimination of 3 keto-acid (e.g., acetolactate and 2-aceto-2-hydroxybutyrate) and / or aldehyde-derived by-products. In various embodiments described herein, the recombinant microorganisms may be microorganisms of the Saccharomyces clade, Crabtree-negative yeast microorganisms, Crabtree-positive yeast microorganisms, post-WGD (whole genome duplication) yeast microorganisms, pre-WGD (whole genome duplication) yeast microorganisms, and non-fermenting yeast microorganisms.

A novel BC fermentation technique for controlling 3D shape, thickness and architecture of the entangled cellulose nano-fibril network is presented. The resultant nano-cellulose based structures are useful as biomedical implants and devices, are useful for tissue engineering and regenerative medicine, and for health care products. More particularly, embodiments of the present invention relate to systems and methods for the production and control of 3-D architecture and morphology of nano-cellulose biomaterials produced by bacteria using any biofabrication process, including the novel 3-D Bioprinting processes disclosed. Representative processes according to the invention involve control of the rate of production of biomaterial by bacteria achieved by meticulous control of the addition of fermentation media using a microfluidic system. In exemplary embodiments, the bacteria gradually grew up along the printed alginate structure that had been placed into the culture, incorporating it. After culture, the printed alginate structure was successfully removed revealing porosity where the alginate had been placed. Porosity and interconnectivity of pores in the resultant 3-D architecture can be achieved by porogen introduction using, e.g., ink-jet printer technology.

The present invention relates to mutant microorganisms having improved productivity of branched-chain amino acids, and a method for producing branched-chain amino acids using the mutant microorganisms. More specifically, relates to mutant microorganisms having improved productivity of L-valine, which are produced by attenuating or deleting a gene encoding an enzyme involved in L-isoleucine biosynthesis, a gene encoding an enzyme involved in L-leucine, and a gene encoding an enzyme involved in D-pantothenic acid biosynthesis, and mutating a gene encoding an enzyme involved in L-valine biosynthesis, such that the expression thereof is increased, as well as a method for producing L-valine using the mutant microorganisms. The inventive mutant microorganisms produced by site-specific mutagenesis and metabolic pathway engineering can produce branched-chain amino acids, particularly L-valine, with high efficiency, and thus will be useful as industrial microorganisms for producing L-valine.

The present invention provides methods, enzymes, and cells for the biosynthetic production of phloroglucinol from malonyl-CoA, which is ultimately obtained from simple starting materials such as glucose; also provided are methods for preparing derivatives of biosynthetic phloroglucinol, including, e.g., resorcinol.

The invention discloses a method for preparing steviol by carrying out catalytic hydrolysis on stevioside by beta-glucosidase, belonging to the field of biosynthesis technology of organic compounds. The method takes the beta-glucosidase derived from aspergillus niger as a catalyst, and can be used for preparing the steviol by carrying out catalytic hydrolysis on the stevioside in single stevioside or stevia rebaudiana extract through temperature programming; the method has the advantages of being high in conversion rate and selectivity, simple in separation and the like; and the enzyme activity loss can be reduced by the temperature programming reaction, so that the utilization rate of enzyme can be improved. The invention provides a new method for preparing the steviol, which is efficient and environment-friendly.

A non-naturally occurring microbial organism has at least one exogenous nucleic acid encoding a MEK pathway enzyme expressed in a sufficient amount to produce MEK. The MEK pathway includes an enzyme selected from an acetoacetyl-CoA dehydrogenase (bifunctional), an acetoacetyl-CoA aldehyde dehydrogenase, a 3-oxobutyraldehyde reductase, a 3-oxobutanol dehydratase, an MEK oxidoreductase, a 3-oxobutyraldehyde aminotransferase, a 4-aminobutan-2-one deaminase, a 2-amino-4-ketopentanoate (AKP) thiolase, an AKP aminotransferase, a 2,4-dioxopentanoate decarboxylase, an AKP deaminase, an acetylacrylate decarboxylase, an AKP decarboxylase, a glutamate dehydrogenase, a 3-oxobutyraldehyde oxidoreductase (aminating) and an AKP oxidoreductase (aminating). A 2-butanol pathway further includes an MEK reductase. A method for producing MEK or 2-butanol includes culturing these organisms under conditions and for a sufficient period of time to produce MEK or 2-butanol.